Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus Nature Reviews Endocrinology Everyone and their mother is talking about eloralintide, the new amylin receptor agonist showing up to 20% body weight reduction in early trials. Gabriel Alizaidy, MD, MS Development of a Long Acting and Stapled Dual Amylin and Calcitonin Receptor Agonist as Monotherapy and Combination with GLP 1R Agonists for the Treatment of Obesity Bioconjugate Chemistry Eloralintide Lilly's Amylin Agonist Outperforms Novo's Cagrilintide at 48 Weeks The evolving landscape of obesity pharmacotherapy Nature Reviews Drug Discovery, 2026 1 Obesity pharmacotherapy has moved from weight loss drugs to cardiometabolic disease modifying therapy Obesity is now framed as a chronic, relapsing, Amylin based therapies are emerging as promising obesity medications. Eloralintide is a novel, selective amylin receptor agonist in development for weight management, type 2 diabetes and more! Eloralintide, a selective amylin receptor agonist